Eintrag weiter verarbeiten
Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer
Gespeichert in:
| Zeitschriftentitel: | The Oncologist |
|---|---|
| Personen und Körperschaften: | , , , , , |
| In: | The Oncologist, 22, 2017, 1, S. 70-80 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
Oxford University Press (OUP)
|
| Schlagwörter: |
| author_facet |
O’Kane, Grainne M. Labbé, Catherine Doherty, Mark K. Young, Kelvin Albaba, Hamzeh Leighl, Natasha B. O’Kane, Grainne M. Labbé, Catherine Doherty, Mark K. Young, Kelvin Albaba, Hamzeh Leighl, Natasha B. |
|---|---|
| author |
O’Kane, Grainne M. Labbé, Catherine Doherty, Mark K. Young, Kelvin Albaba, Hamzeh Leighl, Natasha B. |
| spellingShingle |
O’Kane, Grainne M. Labbé, Catherine Doherty, Mark K. Young, Kelvin Albaba, Hamzeh Leighl, Natasha B. The Oncologist Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer Cancer Research Oncology |
| author_sort |
o’kane, grainne m. |
| spelling |
O’Kane, Grainne M. Labbé, Catherine Doherty, Mark K. Young, Kelvin Albaba, Hamzeh Leighl, Natasha B. 1083-7159 1549-490X Oxford University Press (OUP) Cancer Research Oncology http://dx.doi.org/10.1634/theoncologist.2016-0164 <jats:title>Abstract</jats:title><jats:p>Monoclonal antibodies targeting programmed cell death protein-1 (PD-1) represent a new treatment paradigm in non-small cell lung cancer. Three phase III trials have demonstrated a survival benefit and improved tolerability of nivolumab and pembrolizumab when compared with standard second-line chemotherapy. Nevertheless, the adverse events associated with PD-1 inhibitors are unique; early recognition and treatment are essential. This review summarizes the required monitoring and appropriate management of immune-related adverse events in lung cancer patients receiving these agents.</jats:p> Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer The Oncologist |
| doi_str_mv |
10.1634/theoncologist.2016-0164 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTYzNC90aGVvbmNvbG9naXN0LjIwMTYtMDE2NA |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTYzNC90aGVvbmNvbG9naXN0LjIwMTYtMDE2NA |
| institution |
DE-105 DE-14 DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 |
| imprint |
Oxford University Press (OUP), 2017 |
| imprint_str_mv |
Oxford University Press (OUP), 2017 |
| issn |
1083-7159 1549-490X |
| issn_str_mv |
1083-7159 1549-490X |
| language |
English |
| mega_collection |
Oxford University Press (OUP) (CrossRef) |
| match_str |
okane2017monitoringandmanagementofimmunerelatedadverseeventsassociatedwithprogrammedcelldeathprotein1axisinhibitorsinlungcancer |
| publishDateSort |
2017 |
| publisher |
Oxford University Press (OUP) |
| recordtype |
ai |
| record_format |
ai |
| series |
The Oncologist |
| source_id |
49 |
| title |
Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer |
| title_unstemmed |
Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer |
| title_full |
Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer |
| title_fullStr |
Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer |
| title_full_unstemmed |
Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer |
| title_short |
Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer |
| title_sort |
monitoring and management of immune-related adverse events associated with programmed cell death protein-1 axis inhibitors in lung cancer |
| topic |
Cancer Research Oncology |
| url |
http://dx.doi.org/10.1634/theoncologist.2016-0164 |
| publishDate |
2017 |
| physical |
70-80 |
| description |
<jats:title>Abstract</jats:title><jats:p>Monoclonal antibodies targeting programmed cell death protein-1 (PD-1) represent a new treatment paradigm in non-small cell lung cancer. Three phase III trials have demonstrated a survival benefit and improved tolerability of nivolumab and pembrolizumab when compared with standard second-line chemotherapy. Nevertheless, the adverse events associated with PD-1 inhibitors are unique; early recognition and treatment are essential. This review summarizes the required monitoring and appropriate management of immune-related adverse events in lung cancer patients receiving these agents.</jats:p> |
| container_issue |
1 |
| container_start_page |
70 |
| container_title |
The Oncologist |
| container_volume |
22 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792336062230560779 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T14:54:05.144Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Monitoring+and+Management+of+Immune-Related+Adverse+Events+Associated+With+Programmed+Cell+Death+Protein-1+Axis+Inhibitors+in+Lung+Cancer&rft.date=2017-01-01&genre=article&issn=1549-490X&volume=22&issue=1&spage=70&epage=80&pages=70-80&jtitle=The+Oncologist&atitle=Monitoring+and+Management+of+Immune-Related+Adverse+Events+Associated+With+Programmed+Cell+Death+Protein-1+Axis+Inhibitors+in+Lung+Cancer&aulast=Leighl&aufirst=Natasha+B.&rft_id=info%3Adoi%2F10.1634%2Ftheoncologist.2016-0164&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792336062230560779 |
| author | O’Kane, Grainne M., Labbé, Catherine, Doherty, Mark K., Young, Kelvin, Albaba, Hamzeh, Leighl, Natasha B. |
| author_facet | O’Kane, Grainne M., Labbé, Catherine, Doherty, Mark K., Young, Kelvin, Albaba, Hamzeh, Leighl, Natasha B., O’Kane, Grainne M., Labbé, Catherine, Doherty, Mark K., Young, Kelvin, Albaba, Hamzeh, Leighl, Natasha B. |
| author_sort | o’kane, grainne m. |
| container_issue | 1 |
| container_start_page | 70 |
| container_title | The Oncologist |
| container_volume | 22 |
| description | <jats:title>Abstract</jats:title><jats:p>Monoclonal antibodies targeting programmed cell death protein-1 (PD-1) represent a new treatment paradigm in non-small cell lung cancer. Three phase III trials have demonstrated a survival benefit and improved tolerability of nivolumab and pembrolizumab when compared with standard second-line chemotherapy. Nevertheless, the adverse events associated with PD-1 inhibitors are unique; early recognition and treatment are essential. This review summarizes the required monitoring and appropriate management of immune-related adverse events in lung cancer patients receiving these agents.</jats:p> |
| doi_str_mv | 10.1634/theoncologist.2016-0164 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTYzNC90aGVvbmNvbG9naXN0LjIwMTYtMDE2NA |
| imprint | Oxford University Press (OUP), 2017 |
| imprint_str_mv | Oxford University Press (OUP), 2017 |
| institution | DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1 |
| issn | 1083-7159, 1549-490X |
| issn_str_mv | 1083-7159, 1549-490X |
| language | English |
| last_indexed | 2024-03-01T14:54:05.144Z |
| match_str | okane2017monitoringandmanagementofimmunerelatedadverseeventsassociatedwithprogrammedcelldeathprotein1axisinhibitorsinlungcancer |
| mega_collection | Oxford University Press (OUP) (CrossRef) |
| physical | 70-80 |
| publishDate | 2017 |
| publishDateSort | 2017 |
| publisher | Oxford University Press (OUP) |
| record_format | ai |
| recordtype | ai |
| series | The Oncologist |
| source_id | 49 |
| spelling | O’Kane, Grainne M. Labbé, Catherine Doherty, Mark K. Young, Kelvin Albaba, Hamzeh Leighl, Natasha B. 1083-7159 1549-490X Oxford University Press (OUP) Cancer Research Oncology http://dx.doi.org/10.1634/theoncologist.2016-0164 <jats:title>Abstract</jats:title><jats:p>Monoclonal antibodies targeting programmed cell death protein-1 (PD-1) represent a new treatment paradigm in non-small cell lung cancer. Three phase III trials have demonstrated a survival benefit and improved tolerability of nivolumab and pembrolizumab when compared with standard second-line chemotherapy. Nevertheless, the adverse events associated with PD-1 inhibitors are unique; early recognition and treatment are essential. This review summarizes the required monitoring and appropriate management of immune-related adverse events in lung cancer patients receiving these agents.</jats:p> Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer The Oncologist |
| spellingShingle | O’Kane, Grainne M., Labbé, Catherine, Doherty, Mark K., Young, Kelvin, Albaba, Hamzeh, Leighl, Natasha B., The Oncologist, Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer, Cancer Research, Oncology |
| title | Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer |
| title_full | Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer |
| title_fullStr | Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer |
| title_full_unstemmed | Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer |
| title_short | Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer |
| title_sort | monitoring and management of immune-related adverse events associated with programmed cell death protein-1 axis inhibitors in lung cancer |
| title_unstemmed | Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer |
| topic | Cancer Research, Oncology |
| url | http://dx.doi.org/10.1634/theoncologist.2016-0164 |